Multiple Myeloma

The CD38-specific monoclonal antibody SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.

The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

James R. Berenson, MD, discusses a phase I study presented at the 2013 ASH meeting that analyzed the use weekly carfilzomib for patients with R/R multiple myeloma.

An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the administration of carfilzomib.

Pomalidomide (Pomalyst) rode impressive trial results to accelerated FDA approval this year, and Kenneth Anderson thinks it will prove a valuable new tool in the fight against multiple myeloma

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.

The investigational cancer medications being developed by Stemline Therapeutics attack only a tiny percentage of all tumor cells. But those few cells-the stem cells that resist most treatment and drive tumor growth-may just be the most important ones.

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

Several protocols of novel immune and targeted agents show promise alone and in combination, including monoclonal antibodies, immune therapies, and newer proteasome inhibitors.

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide, as well as research involving the novel agents daratumumab and elotuzumab.

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.

Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival.

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with multiple myeloma.